⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Fermenta Biotech Limited (FERMENTA) — Board Meeting | 11 August 2026(2 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable Neutral 📄 PDF
📢 Key Event
Fermenta Biotech approved ₹110 crore capex for plant-source Vitamin D3 and green chemistry expansion, secured EDQM CEP certification, and reported FY26 revenue of ₹548 crore.
🔄 What Changed
Revenue grew 14% YoY to ₹548 crore; core EBITDA up 44% to ₹120 crore; PAT at ₹70 crore; EDQM CEP certification obtained; ₹110 crore capex approved.
🔮 What's Next
The company plans to commercialize plant-source Vitamin D3 and Calcifediol, scale green chemistry capabilities, and pursue selective acquisitions to expand its footprint in preventive health and fortified food markets.
💡 Investor Takeaway
Fermenta is transitioning from recovery to broad-based growth with scalable, high-margin products and a strong balance sheet, positioning it for sustained value creation.

Fermenta Biotech reported record FY26 revenue of ₹548 crore, up 14% from ₹481 crore, with core EBITDA rising 44% to ₹120 crore and PAT at ₹70 crore. The company secured EDQM CEP certification for plant-source Vitamin D3, approved ₹110 crore capex for new capacity, and expanded its global footprint through certifications and partnerships. It emphasized innovation in green chemistry, backward integration, and diversification beyond nutrition, targeting preventive health and fortified food markets. The AGM highlighted strong financial resilience, low leverage, and a strategic focus on scaling high-margin Vitamin D3 and enzyme products while maintaining a deleveraged balance sheet.

2 Board Meeting 🟡 Notable Neutral 📄 PDF
📢 Key Event
Board approved unaudited financial results for Q1 FY27 and limited review reports.
🔄 What Changed
Approved unaudited standalone and consolidated results for Q1 FY27; issued limited review reports with unmodified opinion.
💡 Investor Takeaway
The board finalized and disclosed Q1 financials, confirming no material changes beyond standard reporting.

Fermenta Biotech announced the outcome of its August 11, 2026 board meeting, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with limited review reports from SRBC & Co. LLP, which issued an unmodified opinion on the results.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — FERMENTA ✨ Ask AI About This

About Fermenta Biotech Limited (FERMENTA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹1,471.99 Cr P/E: 24.3 ROE: 14.3% ROCE: 18.1% Div Yield: 0.75%

View full FERMENTA stock details →

📡 Get AI alerts when FERMENTA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FERMENTA — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More FERMENTA filings

See all FERMENTA filings →

🔥 Also filed on 11 August 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FERMENTA files new disclosures

Track FERMENTA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FERMENTA — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd